A phase III, randomized study of 3 + 7 + quizartinib versus 3 + 7 in frontline FLT3-ITD AML completed enrollment; the results are expected in 2021 (QUANTUM-First, NCT02668653). The gene discussed is FLT3; the disease is acute myeloid leukemia.